Paper3396010
Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen.
Muraro R and 9 others. Cancer Res, 1988. Cited by 259 papers, by iCite.
Cite this record
ConductScience Library. Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen. Papers, record 3396010. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3396010
- Cell line
- B72.33 papers
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen.
- PubMed
Connected records8
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Cell lines8
- B72.3Cellosaurus cites the paper3 papers
- CC 49Cellosaurus cites the paper3 papers
- CC 11Cellosaurus cites the paper2 papers
- CC 15Cellosaurus cites the paper2 papers
- CC 29Cellosaurus cites the paper2 papers
- CC 30Cellosaurus cites the paper2 papers
- CC 83Cellosaurus cites the paper2 papers
- CC 92Cellosaurus cites the paper2 papers
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal | Major topic |
| Antigens, Neoplasm | Major topic |
| Glycoproteins | Major topic |
| Animals | |
| Antigens, Surface | |
| Breast Neoplasms | |
| Colonic Neoplasms | |
| Female | |
| Humans | |
| Immunohistochemistry | |
| Mice | |
| Mice, Inbred BALB C | |
| Radioimmunoassay |
Source PubMed
Cited by45
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 259 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42780573 | Carbohydrate antigen 72-4 and tumor-associated glycoprotein 72 - tumor marker: Past, present and future. | World J Gastrointest Pathophysiol | 2026 | https://conductscience.org/library/papers/42780573 | PubMed |
| 42677388 | From Glycocode to Precision Oncology: Therapeutic Strategies Targeting Aberrant O-GalNAc Glycosylation in Cancer. | Chem Rev | 2026 | https://conductscience.org/library/papers/42677388 | PubMed |
| 42340347 | Cancer-associated alterations in O-GalNAc glycosylation. | Glycobiology | 2026 | https://conductscience.org/library/papers/42340347 | PubMed |
| 40925376 | Pan-carcinoma sialyl-Tn-targeting expands CAR therapy to solid tumors. | Cell Rep Med | 2025 | https://conductscience.org/library/papers/40925376 | PubMed |
| 40361381 | Development and Potent Anti-Tumor Activity of a Fully Humanized Anti-TAG-72-IL-2 Fusion Protein for Therapy of Solid Tumors. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40361381 | PubMed |
| 40169149 | Antibody numbering schemes: advances, comparisons and tools for antibody engineering. | Protein Eng Des Sel | 2025 | https://conductscience.org/library/papers/40169149 | PubMed |
| 37614264 | Prognostic Value of Tumor Markers in Gastric Cancer: A Tertiary Cancer Centre Experience. | Cureus | 2023 | https://conductscience.org/library/papers/37614264 | PubMed |
| 37509200 | Aberrant Glycosylation as Immune Therapeutic Targets for Solid Tumors. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37509200 | PubMed |
| 37305274 | Deciphering Protein O-GalNAcylation: Method Development and Disease Implication. | ACS Omega | 2023 | https://conductscience.org/library/papers/37305274 | PubMed |
| 37284439 | Smaller size packs a stronger punch - Recent advances in small antibody fragments targeting tumour-associated carbohydrate antigens. | Theranostics | 2023 | https://conductscience.org/library/papers/37284439 | PubMed |
| 36686742 | The (Sialyl) Tn antigen: Contributions to immunosuppression in gastrointestinal cancers. | Front Oncol | 2022 | https://conductscience.org/library/papers/36686742 | PubMed |
| 35158915 | Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35158915 | PubMed |
| 34950576 | Survival Advantage Following TAG-72 Antigen-Directed Cancer Surgery in Patients With Colorectal Carcinoma: Proposed Mechanisms of Action. | Front Oncol | 2021 | https://conductscience.org/library/papers/34950576 | PubMed |
| 33614914 | Engineered CAR-T cells targeting TAG-72 and CD47 in ovarian cancer. | Mol Ther Oncolytics | 2021 | https://conductscience.org/library/papers/33614914 | PubMed |
| 32620701 | TAG-72-Targeted α-Radionuclide Therapy of Ovarian Cancer Using 225Ac-Labeled DOTAylated-huCC49 Antibody. | J Nucl Med | 2021 | https://conductscience.org/library/papers/32620701 | PubMed |
| 32368864 | Improved targeting of an anti-TAG-72 antibody drug conjugate for the treatment of ovarian cancer. | Cancer Med | 2020 | https://conductscience.org/library/papers/32368864 | PubMed |
| 32308758 | Esophageal, gastric and colorectal cancers: Looking beyond classical serological biomarkers towards glycoproteomics-assisted precision oncology. | Theranostics | 2020 | https://conductscience.org/library/papers/32308758 | PubMed |
| 30510550 | Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells. | Front Immunol | 2018 | https://conductscience.org/library/papers/30510550 | PubMed |
| 28513912 | Improving theranostics in pancreatic cancer. | J Surg Oncol | 2017 | https://conductscience.org/library/papers/28513912 | PubMed |
| 26270678 | Challenges in Antibody Development against Tn and Sialyl-Tn Antigens. | Biomolecules | 2015 | https://conductscience.org/library/papers/26270678 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/3396010
GET https://conductscience.org/api/papers/v1/3396010/cited_by?page=2